ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
PRMT5 is a prognostic-related biomarker associated with the tumor immune microenvironment in lung adenocarcinoma.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundProtein arginine methyltransferase 5 (PRMT5) is an arginine methyltransferase that can methylate both histone and non-histone proteins. It has multiple roles, most notably in the development of cancers, including lung adenocarcinoma (LUAD). However, its prognostic value and immune involvement in LUAD remain to be elucidated.
methodsPRMT5 expression in LUAD was analyzed using TIMER and UALCAN, validated by Western blot and immunohistochemical (IHC) assays. Knockdown experiments assessed its effect on proliferation. GEPIA was used for survival analysis. GSCA examined correlations with copy number variants and methylation. TIMER and TISIDB evaluated immune infiltration and chemokine profiles. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed.
resultsTIMER and UALCAN revealed high PRMT5 expression in various tumor types, including LUAD, as confirmed by Western blot and IHC. PRMT5 knockdown significantly reduced cell proliferation, indicating a tumor promoting role. GEPIA analysis identified PRMT5 as a risk factor for poor overall survival in LUAD. PRMT5 expression showed positive association with copy number variants but negative with methylation from GSCA. Further analyses showed that PRMT5 expression was negatively correlated with most immunocytes and chemokines in LUAD from TISIDB. These results indicate PRMT5 contributes significantly to LUAD through immune infiltration. Finally, KEGG analysis showed negative associations of PRMT5 expression with immune and inflammation-related pathways.
conclusionThese findings demonstrate that PRMT5 has potential as a prognostic biomarker and as an immunomodulatory target in LUAD.
Indexed as
Identifiers
42247115What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.